Insulet Analyst Ratings
Citi Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $275
Insulet Is Maintained at Buy by Canaccord Genuity
CCORF Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $269
Insulet Analyst Ratings
Piper Sandler Maintains Insulet(PODD.US) With Buy Rating, Raises Target Price to $285
Piper Sandler Sticks to Its Buy Rating for Insulet (PODD)
Morgan Stanley Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $234
Wells Fargo Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $245
Strong Growth and Market Leadership Support Buy Rating for Insulet
Jefferies Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $260
A Quick Look at Today's Ratings for Insulet(PODD.US), With a Forecast Between $230 to $264
Piper Sandler Sticks to Their Buy Rating for Insulet (PODD)
Insulet's Omnipod 5 Expansion Into Type 2 Diabetes Market: A Strong Buy Rating
Buy Rating on Insulet: Early FDA Approval and Market Dominance Signal Strong Growth Potential
TD Cowen Maintains Insulet(PODD.US) With Buy Rating, Maintains Target Price $264
Insulet (PODD) Gets a Buy From TD Cowen
Analysts Offer Insights on Healthcare Companies: Insulet (PODD), Carisma Therapeutics (CARM) and Recursion Pharmaceuticals (RXRX)
The Latest Analyst Ratings For Insulet
Insulet Analyst Ratings